Integer (NYSE:ITGR) Updates FY 2024 Earnings Guidance

Integer (NYSE:ITGR) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.010-5.430 for the period, compared to the consensus earnings per share estimate of 5.310. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Integer also updated its FY24 guidance to $5.01-5.43 EPS.

Integer Price Performance

Shares of NYSE:ITGR traded down $1.57 during trading on Friday, reaching $109.58. The stock had a trading volume of 604,251 shares, compared to its average volume of 492,104. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.71 and a current ratio of 3.32. The business has a fifty day moving average price of $113.11 and a 200-day moving average price of $99.78. The stock has a market cap of $3.67 billion, a PE ratio of 37.92, a PEG ratio of 1.54 and a beta of 1.10. Integer has a 1-year low of $69.40 and a 1-year high of $123.99.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. The business’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.87 earnings per share. On average, equities analysts forecast that Integer will post 5.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Benchmark reiterated a buy rating and set a $130.00 price objective on shares of Integer in a research report on Friday. CL King assumed coverage on Integer in a research report on Thursday, March 14th. They set a buy rating and a $137.00 price objective on the stock. KeyCorp lifted their price objective on Integer from $123.00 to $139.00 and gave the stock an overweight rating in a research report on Tuesday, April 9th. Finally, Bank of America upgraded Integer from a neutral rating to a buy rating and lifted their price objective for the stock from $105.00 to $135.00 in a research report on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $120.50.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.